益丰药房：政策拐点催生行情，行业整合时代开启

Summary of Yifeng Pharmacy Chain Conference Call Company Overview - Company: Yifeng Pharmacy Chain (603939.SS) - Market Cap: Rmb30,079 million (US$4,313 million) as of January 23, 2026 [2] Industry Insights - Policy Change: The release of the "Opinions on Promoting the High-Quality Development of the Pharmaceutical Retail Industry" by nine central government departments, including the Ministry of Commerce, marks a significant turning point for the pharmaceutical retail sector [1][4] - Shift in Strategy: The policy encourages a transition from a period of rectification to one of active support for high-quality growth and integration within the industry [1] - Consolidation Trend: The policy explicitly supports horizontal mergers and acquisitions among retail pharmacies and promotes vertical integration between wholesale and retail operations, which is expected to accelerate industry consolidation [4] Key Takeaways from the Policy 1. Support for Mergers and Acquisitions: The policy streamlines the process for transferring licenses and insurance qualifications for acquired stores, allowing original qualifications to remain active until new ones are issued [4] 2. Prescription Outflow: Encouragement for the flow of prescriptions from hospitals to retail pharmacies and the development of electronic prescription platforms [4] 3. Insurance Integration: Aims to optimize outpatient reimbursement services at designated retail pharmacies, aligning payment standards with local primary care institutions [4] 4. Centralized Procurement: Retail pharmacies are encouraged to participate in centralized drug procurement programs to enhance bargaining power and reduce costs [4] 5. Remote Services: Allows chain pharmacy headquarters to establish centralized pharmaceutical service platforms for remote prescription review and consultation by licensed pharmacists [4] 6. New Business Models: Supports the expansion of services to include health consulting and management, and encourages brand-name chains to establish a presence in communities [5] Financial Outlook - Target Price: Rmb32.00 per share, derived from DCF analysis with a terminal growth rate of 3% and a WACC of 11.5% [6] - Valuation Metrics: Attractive valuation at 16x 2026E PE, with a strong cash position of over Rmb8 billion as of Q3 2025 [1] Investment Recommendation - Rating: Maintain Buy rating on Yifeng Pharmacy, positioned to capitalize on the consolidation trend [1] - Expected Returns: Anticipated share price return of 29.0% and expected total return of 32.0% [2] Risks - Key Risks: 1. Lower-than-expected growth due to slower pharmacy network penetration [7] 2. Unfavorable policies regarding prescription outflow [7] 3. Low-quality M&A activity that fails to generate synergies [7] Conclusion Yifeng Pharmacy Chain is well-positioned to benefit from the supportive policy environment and industry consolidation, with a strong financial foundation and attractive valuation metrics. The investment outlook remains positive, although potential risks must be monitored closely.